Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEPION: Epigenetic and Immune Targeting in Pancreatic Cancer
NCT04257448Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- May 2020
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of romidepsin, azacitidine, durvalumab, lenalidomide in pancreatic ductal adenocarcinoma (PDAC), sponsored by GWT-TUD. Started May 2020; status: completed.
02
Drugs
romidepsinazacitidinedurvalumablenalidomide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04257448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04257448.